The State Research Center Institute of Immunology of the Federal Medical and Biological Agency (FMBA) has submitted an application for the registration of MIR-19 drug. The entry in the state register of medicines appeared on October 14.
The active ingredients of the drug are synthetic small interfering double-stranded ribonucleic acid (microRNA) and a carrier peptide. According to the entry in the State Register of Medicines (GRLS), MIR-19 will be produced in the form of a lyophilizate of 0.088 mg / 1.762 mg, with a shelf life of 1 year.
The drug, with the help of its active component, small interfering RNAs (siRNAs), specifically destroys a targeted part of the virus genome responsible for its replication (ability to reproduce). However, it does not affect the human genome, since during its development, specific parts of the virus genome were selected that are absent in the human genome, which makes it absolutely safe for humans.
